MA47043A1 - Composés indole carboxamides utiles comme inhibiteurs de kinase - Google Patents

Composés indole carboxamides utiles comme inhibiteurs de kinase

Info

Publication number
MA47043A1
MA47043A1 MA47043A MA47043A MA47043A1 MA 47043 A1 MA47043 A1 MA 47043A1 MA 47043 A MA47043 A MA 47043A MA 47043 A MA47043 A MA 47043A MA 47043 A1 MA47043 A1 MA 47043A1
Authority
MA
Morocco
Prior art keywords
compounds
kinase inhibitors
compounds useful
carboxamide compounds
indole carboxamide
Prior art date
Application number
MA47043A
Other languages
English (en)
Other versions
MA47043B1 (fr
Inventor
Qingjie Liu
Saleem Ahmad
Joseph A Tino
John E Macor
Andrew J Tebben
Hua Gong
Douglas G Batt
Khehyong Ngu
Scott Hunter Watterson
Weiwei Guo
Bertrand Myra Beaudoin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA47043A1 publication Critical patent/MA47043A1/fr
Publication of MA47043B1 publication Critical patent/MA47043B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne des composés de formule (i), ou un sel de ces composés, x représentant cr4 ou n, et r1, r2, r3, r4 et a étant tels que définis dans la description. L'invention concerne également des procédés d'utilisation de ces composés comme inhibiteurs de la tyrosine kinase de bruton (btk), ainsi que des compositions pharmaceutiques comprenant ces composés. Ces composés sont utiles dans le traitement, la prévention ou le ralentissement de la progression de maladies ou de troubles dans une diversité de domaines thérapeutiques, tels que les maladies auto-immunes et les maladies vasculaires.
MA47043A 2014-10-24 2015-10-23 Composés indole carboxamides utiles comme inhibiteurs de kinase MA47043B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068225P 2014-10-24 2014-10-24
PCT/US2015/057055 WO2016065226A1 (fr) 2014-10-24 2015-10-23 Composés indolecarboxamides utiles comme inhibiteurs de kinase

Publications (2)

Publication Number Publication Date
MA47043A1 true MA47043A1 (fr) 2021-03-31
MA47043B1 MA47043B1 (fr) 2021-09-30

Family

ID=54427877

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40301A MA40301B1 (fr) 2014-10-24 2015-10-23 Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA47043A MA47043B1 (fr) 2014-10-24 2015-10-23 Composés indole carboxamides utiles comme inhibiteurs de kinase

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA40301A MA40301B1 (fr) 2014-10-24 2015-10-23 Composés indolecarboxamides utiles comme inhibiteurs de kinase

Country Status (35)

Country Link
US (8) US9688629B2 (fr)
EP (2) EP3461821B1 (fr)
JP (1) JP6517928B2 (fr)
KR (2) KR102030305B1 (fr)
CN (2) CN107108583B (fr)
AR (2) AR102426A1 (fr)
AU (2) AU2015335694B2 (fr)
CA (1) CA2965517C (fr)
CL (1) CL2017000992A1 (fr)
CO (1) CO2017004481A2 (fr)
CY (2) CY1123401T1 (fr)
DK (2) DK3209656T3 (fr)
EA (2) EA032277B1 (fr)
ES (2) ES2809974T3 (fr)
HR (2) HRP20200819T1 (fr)
HU (2) HUE050592T2 (fr)
IL (2) IL251797B (fr)
LT (2) LT3209656T (fr)
MA (2) MA40301B1 (fr)
ME (2) ME03807B (fr)
MX (2) MX377837B (fr)
MY (2) MY188048A (fr)
PE (2) PE20190710A1 (fr)
PH (2) PH12017500725B1 (fr)
PL (2) PL3209656T3 (fr)
PT (2) PT3209656T (fr)
RS (2) RS60312B1 (fr)
SG (3) SG10201903578VA (fr)
SI (2) SI3209656T1 (fr)
SM (2) SMT202000317T1 (fr)
TN (2) TN2017000119A1 (fr)
TW (2) TWI743401B (fr)
UY (1) UY36371A (fr)
WO (1) WO2016065226A1 (fr)
ZA (1) ZA201804893B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201506924YA (en) 2013-03-15 2015-09-29 Incyte Corp Tricyclic heterocycles as bet protein inhibitors
US10508259B2 (en) 2014-01-10 2019-12-17 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light, heat, and negative pressure processes
US10947488B2 (en) 2014-01-10 2021-03-16 Lost Spirits Technology Llc Method for rapid maturation of distilled spirits using light and heat processes
PL3134403T3 (pl) 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
KR102490156B1 (ko) 2014-10-24 2023-01-18 다케다 야쿠힌 고교 가부시키가이샤 헤테로시클릭 화합물
MX2017005060A (es) 2014-10-24 2017-07-05 Bristol Myers Squibb Co Compuestos atropisomeros triciclicos.
RS59707B1 (sr) 2014-10-24 2020-01-31 Bristol Myers Squibb Co Derivati karbazola
CN108884068B (zh) 2016-03-24 2021-02-26 特殊治疗有限公司 作为dub抑制剂的1-氰基-吡咯烷衍生物
CA3028689A1 (fr) 2016-06-20 2017-12-28 Incyte Corporation Formes cristallines solides d'un inhibiteur bet
DK3507282T3 (da) * 2016-09-02 2021-02-01 Bristol Myers Squibb Co Fremgangsmåde til fremstilling af indolcarboxamidforbindelser
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
GB201616627D0 (en) * 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
US20180325931A1 (en) 2017-01-21 2018-11-15 Ningbo Zhiming Biotechnology Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
EP3694528A4 (fr) 2017-10-13 2021-07-28 The Regents of the University of California Modulateurs de mtorc1
CR20200347A (es) 2018-02-13 2020-09-23 Gilead Sciences Inc Inhibidores pd-1/pd-l1
WO2019208805A1 (fr) 2018-04-27 2019-10-31 小野薬品工業株式会社 AGENT PRÉVENTIF ET/OU THÉRAPEUTIQUE POUR MALADIE AUTO-IMMUNE COMPRENANT UN COMPOSÉ AYANT UNE ACTIVITÉ INHIBITRICE DE Btk EN TANT QUE PRINCIPE ACTIF
SG11202012425QA (en) * 2018-07-13 2021-01-28 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
KR20210038877A (ko) 2018-07-25 2021-04-08 노파르티스 아게 Nlrp3 인플라마좀 억제제
CN117285467A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
BR112022009881A2 (pt) * 2019-11-22 2022-10-11 Univ California Inibidores de caspase 6 e usos dos mesmos
JP2023505155A (ja) * 2019-12-04 2023-02-08 アプティニックス インコーポレイテッド 神経変性疾患に関連する認知障害を治療する方法
US12448363B2 (en) * 2020-06-02 2025-10-21 Vidya Therapeutics, Inc. Kinase inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
KR20230049115A (ko) * 2020-08-07 2023-04-12 상하이 메이유에 바이오테크 디벨롭먼트 컴퍼니 리미티드 보체 인자 b 억제제 및 이의 약학적 조성물, 제조 방법 및 용도
WO2022035799A1 (fr) * 2020-08-10 2022-02-17 Prelude Therapeutics Incorporated Inhibiteurs de cdk à hétérocycle et leur utilisation
JP7545570B2 (ja) 2020-08-14 2024-09-04 ノバルティス アーゲー ヘテロアリール置換スピロピペリジニル誘導体及びその薬学的使用
WO2022089620A1 (fr) * 2020-10-30 2022-05-05 苏州晶云药物科技股份有限公司 Nouvelles formes cristallines de composé d'indole carboxamide et procédé de préparation associé
CN117015528A (zh) * 2021-01-12 2023-11-07 Gb005股份有限公司 作为激酶抑制剂的吲哚衍生物
CN114957241B (zh) * 2021-02-23 2023-08-22 药雅科技(上海)有限公司 杂环类化合物作为激酶抑制剂的制备及其应用
CN114853723B (zh) * 2021-02-03 2023-11-24 药雅科技(上海)有限公司 吲哚类化合物btk抑制剂的制备及其应用
CN115141176B (zh) * 2021-03-31 2023-08-22 药雅科技(上海)有限公司 炔代吲哚类fgfr抑制剂及其制备方法和用途
CN116348453B (zh) * 2021-04-25 2025-07-04 烨辉医药科技(上海)有限公司 杂芳族甲酰胺化合物及其用途
CN115368310B (zh) * 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法
US20240383871A1 (en) 2021-08-30 2024-11-21 Bristol-Myers Squibb Company Compound useful for pet-imaging of bruton’s tyrosine kinase
WO2023227080A1 (fr) * 2022-05-25 2023-11-30 百极弘烨(南通)医药科技有限公司 Composé protac, composition pharmaceutique le contenant, son procédé de préparation et son utilisation
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
CN115010665A (zh) * 2022-08-05 2022-09-06 山东省食品药品检验研究院 一种硫酸特布他林杂质b的合成方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (fr) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline-thromboxane-synthetase
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (fr) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certaines imidazo[1,2-a]pyrazin-8-ylamines substituees heterocycliques et methodes d'inhibition de la tyrosine kinase de bruton utilisant ces composes
WO2005047290A2 (fr) 2003-11-11 2005-05-26 Cellular Genomics Inc. Certaines imidazo[1,2-a]pyrazin-8-ylamines, procede de fabrication et methode d'utilisation
CN101060842A (zh) * 2004-09-21 2007-10-24 葛兰素集团有限公司 化合物
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
EP1812439B2 (fr) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
AU2005304473A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
BRPI0517211B8 (pt) 2004-12-17 2021-05-25 Glenmark Pharmaceuticals Sa composto, composição farmacêutica e seu uso.
MX2007011041A (es) 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
EP1869052A1 (fr) 2005-04-06 2007-12-26 AstraZeneca AB Heterocycles substitues et leur utilisation en tant qu inhibiteurs de la chk1, de la pdk1 et de la pak
AR055343A1 (es) * 2005-06-30 2007-08-22 Smithkline Beecham Corp Derivados de indolcarboxamida inhibidores de quinasas ikk2
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
JP5249772B2 (ja) 2005-11-22 2013-07-31 メルク・シャープ・アンド・ドーム・コーポレーション キナーゼの阻害剤として有用な三環式化合物
TWI387585B (zh) 2006-09-01 2013-03-01 Dow Agrosciences Llc 殺蟲性之ｎ-取代（雜芳基）烷基烴基硫亞胺
WO2008033858A2 (fr) 2006-09-11 2008-03-20 Cgi Pharmaceuticals, Inc. Inhibiteurs de kinase et procédés d'utilisation et d'identification des inhibiteurs de kinase
CA2663178C (fr) 2006-09-11 2016-01-12 Matrix Laboratories Ltd. Derives de dibenzofurane comme inhibiteurs de pde-4 et pde-10
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
CN101730699A (zh) 2007-03-21 2010-06-09 百时美施贵宝公司 可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
JP2010525046A (ja) 2007-04-27 2010-07-22 アストラゼネカ アクチボラグ 血液系腫瘍の治療のための方法
WO2008144253A1 (fr) * 2007-05-14 2008-11-27 Irm Llc Inhibiteurs de la protéine kinase et procédé d'utilisation de ceux-ci
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
AU2008335761B2 (en) 2007-12-13 2014-04-24 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2247558B2 (fr) 2008-02-14 2024-07-03 Eli Lilly and Company Nouveaux agents d'imagerie pour la détection d'une dysfonction neurologique
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
US8476430B2 (en) 2008-07-24 2013-07-02 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP2151441A1 (fr) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Dérivés de béta-carboline en tant que substrats pour une enzyme
US8084620B2 (en) 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
EP2415184B1 (fr) 2009-02-13 2019-04-10 Nextivity, Inc. Commande à distance d'un préamplificateur
EP2440204B1 (fr) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Composés de nicotinamide utiles en tant que modulateurs de kinases
US8846673B2 (en) 2009-08-11 2014-09-30 Bristol-Myers Squibb Company Azaindazoles as kinase inhibitors and use thereof
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
WO2011159857A1 (fr) * 2010-06-16 2011-12-22 Bristol-Myers Squibb Company Composés de carboline-carboxamide utiles en tant qu'inhibiteurs de kinases
EP2455378A1 (fr) 2010-11-03 2012-05-23 Philip Morris Products S.A. Dérivés de carbazole et de carboline, et préparation et applications thérapeutiques associées
EP2640729B1 (fr) 2010-11-15 2016-12-21 VIIV Healthcare UK Limited Inhibiteurs de la réplication du vih
WO2012149236A1 (fr) 2011-04-28 2012-11-01 Bristol-Myers Squibb Company Nouveaux modulateurs du récepteur tgr5 sous forme d'hétéroaryles bicycliques contenant de l'azote
AU2012257802A1 (en) 2011-05-17 2013-10-31 F. Hoffmann-La Roche Ag Inhibitors of Bruton's tyrosine kinase
ES2548414T3 (es) * 2011-07-08 2015-10-16 Novartis Ag Novedosos derivados de pirrolo pirimidina
JP6182593B2 (ja) * 2012-04-20 2017-08-16 アドヴィーナス セラピューティクス リミテッド 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
AR091273A1 (es) * 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
ES2660210T3 (es) * 2012-09-07 2018-03-21 Novartis Ag Derivados de indolcarboxamida y usos de los mismos
TWI648272B (zh) 2013-06-25 2019-01-21 美商必治妥美雅史谷比公司 經取代之四氫咔唑及咔唑甲醯胺化合物
AU2014302550A1 (en) 2013-06-25 2016-02-11 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
WO2014210255A1 (fr) * 2013-06-26 2014-12-31 Abbvie Inc. Carboxamides primaires servant d'inhibiteurs de la btk

Also Published As

Publication number Publication date
IL251797B (en) 2020-07-30
MA40301A1 (fr) 2019-03-29
TN2018000218A1 (en) 2019-10-04
US10329274B2 (en) 2019-06-25
MX377837B (es) 2025-03-11
ES2809974T3 (es) 2021-03-08
KR102030305B1 (ko) 2019-10-08
EP3461821A1 (fr) 2019-04-03
US9920031B2 (en) 2018-03-20
EA032277B1 (ru) 2019-05-31
CN110511209A (zh) 2019-11-29
RS60312B1 (sr) 2020-07-31
IL262206A (en) 2018-11-29
SG10201903578VA (en) 2019-05-30
EA034931B1 (ru) 2020-04-08
HUE050592T2 (hu) 2020-12-28
TN2017000119A1 (en) 2018-07-04
PE20170695A1 (es) 2017-05-26
US9688629B2 (en) 2017-06-27
TW201630880A (zh) 2016-09-01
PT3209656T (pt) 2020-06-08
EA201790740A1 (ru) 2017-08-31
WO2016065226A1 (fr) 2016-04-28
CN110511209B (zh) 2022-07-05
US11623921B2 (en) 2023-04-11
US20170260160A1 (en) 2017-09-14
AU2015335694B2 (en) 2020-04-02
CA2965517A1 (fr) 2016-04-28
JP6517928B2 (ja) 2019-05-22
US10604504B2 (en) 2020-03-31
CO2017004481A2 (es) 2017-08-10
IL251797A0 (en) 2017-06-29
KR20180132167A (ko) 2018-12-11
US9802915B2 (en) 2017-10-31
EP3209656A1 (fr) 2017-08-30
CA2965517C (fr) 2023-05-02
SG10201903579SA (en) 2019-05-30
MX2017005259A (es) 2017-07-26
SMT202000412T1 (it) 2020-09-10
ME03807B (fr) 2021-04-20
SI3209656T1 (sl) 2020-07-31
KR102001745B1 (ko) 2019-07-18
UY36371A (es) 2016-04-29
SMT202000317T1 (it) 2020-07-08
KR20170061175A (ko) 2017-06-02
EP3461821B1 (fr) 2020-05-13
MA40301B1 (fr) 2019-12-31
AU2019283921B2 (en) 2021-01-07
PT3461821T (pt) 2020-08-05
MY188048A (en) 2021-11-12
AR120317A2 (es) 2022-02-09
MX393057B (es) 2025-03-24
US20230192645A1 (en) 2023-06-22
MX2020008024A (es) 2022-06-10
NZ754113A (en) 2021-02-26
PH12017500725A1 (en) 2017-10-09
PH12017500725B1 (en) 2017-10-09
IL262206B (en) 2020-07-30
TWI743401B (zh) 2021-10-21
HRP20200819T1 (hr) 2020-08-07
JP2017531679A (ja) 2017-10-26
AU2019283921A1 (en) 2020-01-16
MA47043B1 (fr) 2021-09-30
US20190119245A1 (en) 2019-04-25
ZA201804893B (en) 2020-07-29
CY1123401T1 (el) 2021-12-31
US20200165222A1 (en) 2020-05-28
PL3209656T3 (pl) 2020-12-14
US20170066740A1 (en) 2017-03-09
ES2795366T3 (es) 2020-11-23
NZ731946A (en) 2021-02-26
BR112017007956A2 (pt) 2017-12-19
WO2016065226A8 (fr) 2017-04-27
CL2017000992A1 (es) 2017-11-17
HRP20201146T1 (hr) 2020-10-30
EA201892207A1 (ru) 2019-02-28
PH12020500265A1 (en) 2021-02-22
US20160115126A1 (en) 2016-04-28
HUE050706T2 (hu) 2020-12-28
PL3461821T3 (pl) 2020-10-19
DK3209656T3 (da) 2020-07-13
PE20190710A1 (es) 2019-05-17
EP3209656B1 (fr) 2020-04-01
US20190248760A1 (en) 2019-08-15
TWI744218B (zh) 2021-11-01
SG11201703188QA (en) 2017-05-30
LT3461821T (lt) 2020-08-10
MY195561A (en) 2023-02-02
DK3461821T3 (da) 2020-08-17
AR102426A1 (es) 2017-03-01
ME03740B (fr) 2021-01-20
RS60629B1 (sr) 2020-09-30
SI3461821T1 (sl) 2020-09-30
LT3209656T (lt) 2020-07-27
CN107108583B (zh) 2020-11-13
TW201900612A (zh) 2019-01-01
CN107108583A (zh) 2017-08-29
AU2015335694A1 (en) 2017-06-08
CY1123395T1 (el) 2021-12-31
US20210107891A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA41179A (fr) Composés inhibiteurs de parg
MA38648B1 (fr) Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases
MA40290A1 (fr) Agents immunorégulateurs
MA40955B1 (fr) 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
MA43979B1 (fr) Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques
JO3459B1 (ar) تركيبات صيدلانية لعلاج مرض الزهايمر
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA35460B1 (fr) Composés et compositions en tant qu'inhibiteurs de kinase c-kit
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA39359A1 (fr) Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés
MA38810A1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
EP2563794A4 (fr) Inhibiteurs de l'activité protéine tyrosine kinase et leurs applications au traitement de troubles ophtalmiques
MA39253A1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MA44144A (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA43263B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA45392B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA52220B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales
MA37957A1 (fr) Procédés de traitement de la maladie d'alzheimer et compositions pharmaceutiques associées
MA52370B1 (fr) Dérivés de la pyridine et leurs utilisations thérapeutiques comme inhibiteurs du trpc6
MA39506A1 (fr) Dérivés de 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phényl)-urée utilisés comme inhibiteurs de cxcr2